Polymer-drug conjugates as modulators of cellular apoptosis
- PMID: 17907762
- PMCID: PMC2751409
- DOI: 10.1208/aapsj0902022
Polymer-drug conjugates as modulators of cellular apoptosis
Abstract
The successful clinical application of polymer-protein conjugates (PEGylated enzymes and cytokines) and the promising results arising from clinical trials with polymer-bound chemotherapy (eg, doxorubicin or paclitaxel) have established their potential to reduce toxicity and improve activity in chemotherapy-refractory patients. Furthermore, and more important, they have also provided a firm foundation for more sophisticated second-generation constructs that deliver the newly emerging target-directed bioactive agents (eg, modulators of apoptosis, cell cycle, anti-angiogenic drugs) in addition to polymer-based drug combinations (eg, endocrine therapy and chemotherapy). This review will focus on polymer-drug conjugate modulators of cellular apoptosis to be used as single pro-apoptotic (eg, cancer) or anti-apoptotic (eg, ischemia) agents or as a combination therapy.
Similar articles
-
Polymer conjugates: nanosized medicines for treating cancer.Trends Biotechnol. 2006 Jan;24(1):39-47. doi: 10.1016/j.tibtech.2005.11.006. Epub 2005 Nov 22. Trends Biotechnol. 2006. PMID: 16307811 Review.
-
Polymer-drug conjugates: current status and future trends.Front Biosci. 2008 Jan 1;13:2744-56. doi: 10.2741/2882. Front Biosci. 2008. PMID: 17981750 Review.
-
Micelle-like nanoassemblies based on polymer-drug conjugates as an emerging platform for drug delivery.Expert Opin Drug Deliv. 2012 Jul;9(7):805-22. doi: 10.1517/17425247.2012.689284. Epub 2012 May 19. Expert Opin Drug Deliv. 2012. PMID: 22607499 Review.
-
Polymer--drug conjugates as nano-sized medicines.Curr Opin Biotechnol. 2011 Dec;22(6):894-900. doi: 10.1016/j.copbio.2011.06.003. Epub 2011 Jul 1. Curr Opin Biotechnol. 2011. PMID: 21724381 Review.
-
Polymer-drug conjugates: present state of play and future perspectives.Drug Discov Today. 2013 Dec;18(23-24):1316-22. doi: 10.1016/j.drudis.2013.09.007. Epub 2013 Sep 17. Drug Discov Today. 2013. PMID: 24055841 Review.
Cited by
-
Pharmacological Activities of Schiff Bases and Their Derivatives with Low and High Molecular Phosphonates.Pharmaceuticals (Basel). 2023 Jun 28;16(7):938. doi: 10.3390/ph16070938. Pharmaceuticals (Basel). 2023. PMID: 37513849 Free PMC article. Review.
-
Synthesis of sericin-based conjugates by click chemistry: enhancement of sunitinib bioavailability and cell membrane permeation.Drug Deliv. 2017 Nov;24(1):482-490. doi: 10.1080/10717544.2016.1267822. Drug Deliv. 2017. PMID: 28181828 Free PMC article.
-
Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/Angiogenesis.Molecules. 2016 Nov 2;21(11):1468. doi: 10.3390/molecules21111468. Molecules. 2016. PMID: 27827858 Free PMC article. Review.
-
Synthesis and In Vitro Evaluation of Polyethylene Glycol-Paclitaxel Conjugates for Lung Cancer Therapy.Pharm Res. 2016 Jul;33(7):1671-81. doi: 10.1007/s11095-016-1908-2. Epub 2016 Mar 16. Pharm Res. 2016. PMID: 26984129
-
Nanomedicine--challenge and perspectives.Angew Chem Int Ed Engl. 2009;48(5):872-97. doi: 10.1002/anie.200802585. Angew Chem Int Ed Engl. 2009. PMID: 19142939 Free PMC article. Review.
References
-
- Duncan R. Polymer-drug conjugates. In: Budman D, Calvert H, Rowinsky E, editors. Handbook of Anticancer Drug Development. Baltimore, MD: Lippincott Williams & Wilkins; 2003. pp. 239–260.
-
- Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor or agent smanes. Cancer Res. 1986;46:6387–6392. - PubMed
-
- Satchi-Fainaro R, Duncan R, Bames CM. Polymer therapeutics for cancer: current status and future challenges. Adv Polym Sci. 2006;193:1–65. doi: 10.1007/12_024. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical